SecBot SecBot
Insider Cluster (3 insiders) ·Filed May 7, 2026

UTHR

UNITED THERAPEUTICS Corp
NEUTRAL
Impact 2/10
Horizondays Processed6mo ago
Insider cluster: 3 insiders, $1.4M total
Actionable Insight • Neutral

The insider sales are de minimis relative to market cap and are clearly tied to option exercise programs. No bearish signal. Monitor the next 10-Q for any change in Tyvaso DPI growth trajectory or competitive dynamics in inhaled prostacyclins.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$564.94
T+0 close · May 7, 2026 · via day close
Latest settled
−8.13%
T+60 · $519.01
Vs SPY
−12.49%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 8 $564.94entry
  2. T+1 · 6mo ago +0.87%α +0.65% · $569.88
  3. T+5 · 6mo ago +0.64%α +0.43% · $568.58
  4. T+20 · 5mo ago −3.58%α −3.80% · $544.69
  5. T+60 · 3mo ago −8.13%α −12.49% · $519.01
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Three top executives at United Therapeutics (CEO, CFO, General Counsel) executed option exercises and sold a portion of the resulting shares in the week following the company's Q1 2026 earnings release. Total open-market sales were $1.44M, or ~0.006% of the $24.2B market cap, a trivial amount relative to company size. The sales appear to be routine tax- and cash-management transactions tied to option exercises, not a signal of deteriorating fundamentals.

Key Financial Metrics

Direction
selling
Total Value
$1.4M
Insiders
3

Key Facts

  • Total open-market sales by 3 insiders: $1.44M (0.006% of market cap)
  • CEO Martine Rothblatt sold 2,871 shares for $1.63M across 4 trades, but also exercised options on 38,000 shares (mostly non-cash)
  • CFO James Edgemond sold 1,849 shares for $1.05M, while exercising options on 20,000 shares
  • EVP Paul Mahon sold 80 shares for $46.6K, exercising options on 8,300 shares
  • All sales occurred after the May 6 earnings release, which showed a 2% revenue decline and 15% net income decline YoY
  • The cluster is 6 days post-earnings, insiders were cleared to trade after the public release of results

Financial Impact

Open-market sales of $1.44M represent 0.006% of $24.2B market cap, immaterial

insider ownershipfloat

Risk Factors

  • Q1 revenue declined 2% YoY and net income fell 15%, continued erosion in Nebulized Tyvaso and Remodulin could pressure future results
  • Cost of sales surged 44% YoY, partly due to a $26.8M inventory reserve from a commercial supply agreement

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
77% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-UTHR-1778621182895

Track record

123 reports on UTHR

Performance horizon

4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
  2. Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
  3. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
  4. Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
  5. Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  6. Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
  7. Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
  8. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  9. Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
  10. Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
Showing 10 of 123

US Market Status

Market Closed · Opens Wed (11h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 12, 2026